journal
https://read.qxmd.com/read/37734857/hypoxic-burden-to-guide-cpap-treatment-allocation-in-patients-with-obstructive-sleep-apnoea-a-post-hoc-study-of-the-isaacc-trial
#1
JOURNAL ARTICLE
Lucía Pinilla, Neda Esmaeili, Gonzalo Labarca, Miguel Ángel Martinez-Garcia, Gerard Torres, Esther Gracia-Lavedan, Olga Mínguez, Dolores Martínez, Jorge Abad, Maria José Masdeu, Olga Mediano, Carmen Muñoz, Valentín Cabriada, Joaquín Duran-Cantolla, Mercè Mayos, Ramón Coloma, Josep María Montserrat, Mónica de la Peña, Wen-Hsin Hu, Ludovico Messineo, Sehhati MohammadReza, Andrew Wellman, Susan Redline, Scott Sands, Ferran Barbé, Manuel Sánchez-de-la-Torre, Ali Azarbarzin
Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP). Post-hoc analysis of the ISAACC trial (NCT01335087), including non-sleepy patients with acute coronary syndrome (ACS) diagnosed with OSA (apnoea-hypopnoea index ≥15 events·h-1 ) by respiratory polygraphy. Patients were randomised to CPAP or Usual Care and followed for a minimum of 1 year...
September 21, 2023: European Respiratory Journal
https://read.qxmd.com/read/37734856/dupilumab-leads-to-better-controlled-asthma-quality-of-life-in-children-the-voyage-study
#2
JOURNAL ARTICLE
Alessandro G Fiocchi, Wanda Phipatanakul, Robert S Zeiger, Sandy R Durrani, Jeremy Cole, Jérôme Msihid, Rebecca Gall, Juby A Jacob-Nara, Yamo Deniz, Paul J Rowe, David J Lederer, Megan Hardin, Yi Zhang, Asif H Khan
BACKGROUND: Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more detail the impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their caregivers. METHODS: Children aged 6-11 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150 cells·µL-1 or fractional exhaled nitric oxide [FeNO ] ≥20 ppb; n=350) were treated with dupilumab or placebo for 52 weeks in the VOYAGE study...
September 21, 2023: European Respiratory Journal
https://read.qxmd.com/read/37734855/cardiopulmonary-response-to-exercise-in-adults-born-very-preterm
#3
JOURNAL ARTICLE
Jacques Delfrate, Camille Girard-Bock, Daniel Curnier, Delphine Perie, Anik Cloutier, Gabrielle Gascon, Jennifer S Landry, Benoît Masse, Michael K Stickland, Anne Monique Nuyt, Thuy Mai Luu
This study aims to compare cardiopulmonary response to aerobic exercise between young adults born very preterm, including a subgroup with bronchopulmonary dysplasia (BPD), and term controls.Seventy-one adults (18-29 years) born <30 weeks' gestational age (24 with BPD) and 73 term controls were recruited. Assessment included cardiopulmonary exercise testing with impedance cardiography. We compared group differences in peak O2 consumption (peak VO2 ) and in ventilatory and cardiovascular responses to exercise using linear regression analyses...
September 21, 2023: European Respiratory Journal
https://read.qxmd.com/read/37696566/reducing-the-pressure-in-pah-sotatercept-hemodynamics-and-the-right-ventricle
#4
EDITORIAL
Laura C Price, Colm McCabe, Jason Weatherald
No abstract text is available yet for this article.
September 11, 2023: European Respiratory Journal
https://read.qxmd.com/read/37696565/effects-of-sotatercept-on-haemodynamics-and-right-heart-function-analysis-of-stellar-trial
#5
JOURNAL ARTICLE
Rogerio Souza, David B Badesch, H Ardeschir Ghofrani, J Simon R Gibbs, Mardi Gomberg-Maitland, Vallerie V McLaughlin, Ioana R Preston, Aaron B Waxman, Ekkehard Grünig, Grzegorz Kopeć, Gisela Meyer, Karen M Olsson, Stephan Rosenkranz, Jianxin Lin, Amy O Johnson-Levonas, Janethe de Oliveira Pena, Marc Humbert, Marius M Hoeper
BACKGROUND: In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional efficacy endpoints in pre-treated participants with pulmonary arterial hypertension (PAH). METHODS: This post hoc analysis evaluated data from right heart catheterisation (RHC) and echocardiography (ECHO) obtained from the STELLAR trial. Changes from baseline in RHC and ECHO parameters were assessed at 24 weeks...
September 11, 2023: European Respiratory Journal
https://read.qxmd.com/read/37696564/theratyping-cystic-fibrosis-patients-to-guide-elexacaftor-tezacaftor-ivacaftor-out-of-label-prescription
#6
JOURNAL ARTICLE
Elise Dreano, Pierre Régis Burgel, Aurelie Hatton, Naim Bouazza, Benoit Chevalier, Julie Macey, Sylvie Leroy, Isabelle Durieu, Laurence Weiss, Dominique Grenet, Nathalie Stremler, Camille Ohlmann, Philippe Reix, Michele Porzio, Pauline Roux Claude, Natacha Rémus, Benoit Douvry, Sylvie Montcouquiol, Laure Cosson, Julie Mankikian, Jeanne Languepin, Veronique Houdouin, Laurence Le Clainche, Anne Guillaumot, Delphine Pouradier, Adrien Tissot, Pascaline Priou, Laurent Mély, Frederique Chedevergne, Muriel Lebourgeois, Jean Lebihan, Clémence Martin, Flora Zavala, Jennifer Da Silva, Lydie Lemonnier, Mairead Kelly-Aubert, Anita Golec, Pierre Foucaud, Christophe Marguet, Aleksander Edelman, Alexandre Hinzpeter, Paola di Carli, Emmanuelle Girodon, Isabelle Sermet-Gaudelus, Iwona Pranke
OBJECTIVES: Around 20% of people with Cystic Fibrosis (pwCF) do not have access to the triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Europe because they do not carry the F508del allele on the Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) gene. Considering that pwCF carrying rare variants may benefit from ETI, including variants already validated by the Food and Drug Administration (FDA), a compassionate use program was launched in France. PwCF were invited to undergo a nasal brushing to investigate whether the pharmacological rescue of CFTR activity by ETI in Human Nasal Epithelial Cell (HNEC) cultures was predictive of the clinical response...
September 11, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678956/sensory-interventions-to-relieve-dyspnea-in-critically-ill-mechanically-ventilated-patients
#7
JOURNAL ARTICLE
Côme Bureau, Marie-Cécile Niérat, Maxens Decavèle, Isabelle Rivals, Laurence Dangers, Alexandra Beurton, Sara Virolle, Robin Deleris, Julie Delemazure, Julien Mayaux, Capucine Morélot-Panzini, Martin Dres, Thomas Similowski, Alexandre Demoule
RATIONALE: In critically ill patients receiving mechanical ventilation (MV), dyspnea is frequent, severe, and associated with an increased risk of neuropsychological sequelae. We evaluated the efficacy of sensory interventions targeting the brain rather than the respiratory system to relieve dyspnea in MV patients. METHODS: Patients receiving MV for ≥48 h and reporting dyspnea (unidimensional dyspnea visual analogue scale [Dyspnea-VAS]) first underwent increased pressure support, and then, in random order, auditory stimulation (relaxing music versus pink noise) and air flux stimulation (facial versus lower limb)...
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678955/european-respiratory-society-short-guidelines-for-the-use-of-as-needed-ics-formoterol-in-mild-asthma
#8
JOURNAL ARTICLE
Alberto Papi, Diogenes S Ferreira, Ioana Agache, Eugenio Baraldi, Richard Beasley, Guy Brusselle, Courtney Coleman, Mina Gaga, Carolina Maria, Gotera Rivera, Erik Melén, Ian D Pavord, Deborah Peñate Gómez, Daniel Schuermans, Antonio Spanevello, Thomy Tonia, Florence Schleich
Recent clinical trials of as-needed fixed-dose combination of ICS/formoterol have provided new evidence that may warrant a reconsideration of current practice.A task force (TF) was set up by the European Respiratory Society to provide evidence-based recommendations on the use of as-needed ICS/formoterol as treatment for mild asthma. The TF defined two questions that were assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. The TF utilised the outcomes to develop recommendations for a pragmatic guideline for everyday clinical practice...
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678954/mri-pulmonary-artery-flow-detects-lung-vascular-pathology-in-preterms-with-lung-disease
#9
JOURNAL ARTICLE
Friederike Häfner, Alida Kindt, Kathrin Strobl, Kai Förster, Motaharehsadat Heydarian, Erika Gonzalez, Benjamin Schubert, Yvonne Kraus, Dalla Pozza Robert, Andreas W Flemmer, Birgit Ertl-Wagner, Olaf Dietrich, Sophia Stoecklein, Khodr Tello, Anne Hilgendorff
RATIONALE: Pulmonary vascular disease (PVD) affects the majority of preterm neonates with bronchopulmonary dysplasia (BPD) and significantly determines long-term mortality through undetected progression into pulmonary hypertension. OBJECTIVES: To associate characteristics of pulmonary artery (PA) flow and cardiac function with BPD-associated PVD near term using advanced magnetic resonance imaging (MRI) for improved risk stratification. METHODS: Preterms <32 weeks postmenstrual age (PMA) with/without BPD were clinically monitored including standard echocardiography and prospectively enrolled for 3TMRI in spontaneous sleep near term (AIRR study)...
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678953/translated-impact-on-carbon-footprint-from-choice-of-inhaled-therapy-a-danish-scenario
#10
LETTER
Jørgen Vestbo, Kåre Press-Kristensen
No abstract text is available yet for this article.
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678952/derivation-of-a-high-resolution-ct-based-semi-automated-radiographic-score-in-tuberculosis-and-its-relationship-to-bacillary-load-and-antitubercular-therapy
#11
LETTER
Catherine Riou, Elsa du Bruyn, Grace Hyun J Kim, Irene da Costa, Jihey Lee, Alan Sher, Robert J Wilkinson, Brian W Allwood, Jonathan Goldin
No abstract text is available yet for this article.
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678951/from-pre-copd-to-copd-a-simple-low-cost-and-ease-of-implementation-slim-risk-calculator
#12
JOURNAL ARTICLE
Miguel J Divo, Congjian Liu, Francesca Polverino, Peter J Castaldi, Bartolome R Celli, Yohannes Tesfaigzi
INTRODUCTION: The lifetime risk of developing clinical COPD among smokers ranges from 13 to 22%. Identifying at-risk individuals who will develop overt disease in a reasonable time frame may allow for early intervention. We hypothesized that readily available clinical and physiological variables could help identify ever-smokers at higher risk of developing Chronic Airflow Limitation (CAL). METHODS: Among the 2273 Lovelace Smokers' Cohort (LSC) participants, we included 677 (mean age=54 years) with normal spirometry at baseline and a minimum of 3 spirometries, each one year apart...
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678950/the-skeletal-muscle-metaboreflex-a-novel-driver-of-ventilation-dyspnoea-and-pulmonary-haemodynamics-during-exercise-in-pulmonary-arterial-hypertension
#13
LETTER
Michael J Plunkett, Ana Luiza C Sayegh, Tanya J McWilliams, Sasiharan Sithamparanathan, Julian F R Paton, James P Fisher
No abstract text is available yet for this article.
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678949/regular-low-dose-sustained-release-morphine-for-persisting-breathlessness-in-interstitial-lung-disease-a-randomised-double-blind-placebo-controlled-crossover-trial
#14
LETTER
Diana H Ferreira, Magnus Ekström, Sabrina Bajwah, Belinda Fazekas, David C Currow
No abstract text is available yet for this article.
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37678948/real-world-cohort-evaluation-of-the-impact-of-the-antifibrotics-in-patients-with-idiopathic-pulmonary-fibrosis
#15
LETTER
Timothy M Dempsey, Viengneesee Thao, David A Helfinstine, Yu-Hui H Chang, Lindsey Sangaralingham, Andrew H Limper
No abstract text is available yet for this article.
September 7, 2023: European Respiratory Journal
https://read.qxmd.com/read/37652570/real-world-effectiveness-of-airway-clearance-techniques-in-children-with-cystic-fibrosis
#16
JOURNAL ARTICLE
Nicole Filipow, Sanja Stanojevic, Emma Raywood, Harriet Shannon, Gizem Tanriver, Kunal Kapoor, Helen Douglas, Gwyneth Davies, Rachel O'Connor, Nicky Murray, Eleanor Main
BACKGROUND: Cystic Fibrosis (CF) is commonly characterised by thick respiratory mucous. From diagnosis, people with CF are prescribed daily physiotherapy, including airway clearance treatments (ACTs). ACTs consume a large proportion of treatment time, yet the efficacy and effectiveness of ACTs are poorly understood. This study aimed to evaluate associations between quality and quantity of ACTs and lung function in children and young people with CF. METHODS: Project Fizzyo, a longitudinal observational cohort study, used remote-monitoring electronic pressure sensors with 4 different commercial ACT devices to record real-time, breath-by-breath pressure data during usual ACTs undertaken at home over 16 months in 145 children...
August 31, 2023: European Respiratory Journal
https://read.qxmd.com/read/37652569/the-impact-of-the-immune-system-on-lung-injury-and-regeneration-in-chronic-obstructive-pulmonary-disease
#17
JOURNAL ARTICLE
Theodore S Kapellos, Thomas M Conlon, Ali Önder Yildirim, Mareike Lehmann
Chronic obstructive pulmonary disease (COPD) is a devastating respiratory condition that manifests via persistent inflammation, emphysema development and small airway remodeling. Lung regeneration is defined as the ability of the lung to repair itself after injury by the proliferation and differentiation of progenitor cell populations and becomes impaired in the COPD lung as a consequence of cell intrinsic epithelial stem cell defects and signals from the microenvironment. Although the loss of structural integrity and lung regenerative capacity are critical for disease progression, our understanding of the cellular players and molecular pathways that hamper regeneration in COPD remains limited...
August 31, 2023: European Respiratory Journal
https://read.qxmd.com/read/37620042/tailored-psychological-intervention-for-anxiety-or-depression-in-copd-tandem-a-randomised-controlled-trial
#18
JOURNAL ARTICLE
Stephanie J C Taylor, Ratna Sohanpal, Liz Steed, Karen Marshall, Claire Chan, Nahel Yaziji, Amy C Barradell, Paulino Font-Gilabert, Andrew Healey, Richard Hooper, Moira J Kelly, Kristie-Marie Mammoliti, Stefan Priebe, Arvind Rajasekaran, Michael Roberts, Vickie Rowland, Sally J Singh, Melanie Smuk, Martin Underwood, Sarah Waseem, Patrick White, Vari Wileman, Hilary Pinnock
This multi-centre, pragmatic, randomised controlled trial evaluated whether a tailored psychological intervention based on a cognitive behavioural approach for people with COPD and symptoms of anxiety and/or depression improved anxiety or depression compared to usual care (UC).People with COPD and moderate to very severe airways obstruction and Hospital Anxiety and Depression Scale subscales scores indicating mild to moderate anxiety (HADS-A) and/or depression (HADS-D), were randomised 1.25:1, intervention (242): UC (181)...
August 24, 2023: European Respiratory Journal
https://read.qxmd.com/read/37620041/severe-asthma-trajectories-in-adults-findings-from-the-nordstar-cohort
#19
JOURNAL ARTICLE
Anna von Bülow, Susanne Hansen, Patrik Sandin, Olivia Ernstsson, Christer Janson, Lauri Lehtimäki, Hannu Kankaanranta, Charlotte Ulrik, Bernt Bøgvald Aarli, Kirk Geale, Sheila Tuyet Tang, Maija Wolf, Vibeke Backer, Ole Hilberg, Alan Altraja, Helena Backman, Dóra Lúdvíksdóttir, Unnur Steina Björnsdóttir, Paula Kauppi, Thomas Sandström, Asger Sverrild, Valentyna Yasinska, Maritta Kilpeläinen, Barbro Dahlén, Arja Viinanen, Leif Bjermer, Apostolos Bossios, Celeste Porsbjerg
BACKGROUND: There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. Aim: We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma. METHODS: We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform...
August 24, 2023: European Respiratory Journal
https://read.qxmd.com/read/37591537/impact-of-postnatal-dexamethasone-timing-on-preterm-mortality-and-bronchopulmonary-dysplasia-a-propensity-score-analysis
#20
JOURNAL ARTICLE
T'ng Chang Kwok, Lisa Szatkowski, Don Sharkey
INTRODUCTION: Postnatal dexamethasone (PND) is used in high-risk preterm infants after the first week of life to facilitate extubation and prevent bronchopulmonary dysplasia (BPD) but the optimal treatment timing remains unclear. OBJECTIVE: Explore the association between the timing of PND commencement with mortality and respiratory outcomes. METHODS: Retrospective National Neonatal Research Database study of 84,440 premature infants born below 32 weeks of gestational age from 2010-2020 in England and Wales...
August 17, 2023: European Respiratory Journal
journal
journal
20109
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.